Aligos Therapeutics Stock Analysis

Aligos Stock Analysis Notes

About 34.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.48. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aligos Therapeutics recorded a loss per share of 20.94. The entity had not issued any dividends in recent years. The firm had 1:25 split on the 19th of August 2024. Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. The company was incorporated in 2018 and is headquartered in South San Francisco, California. Aligos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people. For more info on Aligos Therapeutics please contact Dr MBA at 800 466 6059 or go to https://www.aligos.com.

Aligos Therapeutics Investment Alerts

Aligos Therapeutics Upcoming and Recent Events

Aligos Largest EPS Surprises

View All Earnings Estimates

Aligos Therapeutics Environmental, Social, and Governance (ESG) Scores

Aligos Stock Institutional Investors

Note, although Aligos Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Aligos Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 65.73 M.

Aligos Profitablity

Management Efficiency

Aligos Therapeutics has return on total asset (ROA) of (0.5029) % which means that it has lost $0.5029 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.1584) %, meaning that it created substantial loss on money invested by shareholders. Aligos Therapeutics' management efficiency ratios could be used to measure how well Aligos Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 4.76 in 2025, despite the fact that Return On Tangible Assets are likely to grow to (1.78). At this time, Aligos Therapeutics' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 13.6 M in 2025, despite the fact that Other Assets are likely to grow to (2 M).

Technical Drivers

As of the 24th of March, Aligos Therapeutics shows the Risk Adjusted Performance of (0.16), mean deviation of 5.49, and Standard Deviation of 7.47. Aligos Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Aligos Therapeutics coefficient of variation and maximum drawdown to decide if Aligos Therapeutics is priced correctly, providing market reflects its regular price of 10.75 per share. Given that Aligos Therapeutics has information ratio of (0.19), we suggest you to validate Aligos Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Aligos Therapeutics Price Movement Analysis

Aligos Therapeutics Insider Trading Activities

Aligos Therapeutics Outstanding Bonds

Aligos Therapeutics Predictive Daily Indicators

Aligos Therapeutics Corporate Filings

Aligos Therapeutics Forecast Models

Aligos Therapeutics' time-series forecasting models are one of many Aligos Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Aligos Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Aligos Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Aligos shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Aligos Therapeutics. By using and applying Aligos Stock analysis, traders can create a robust methodology for identifying Aligos entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Aligos analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Aligos analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Aligos Therapeutics stock analysis indicators help investors evaluate how Aligos Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Aligos Therapeutics shares will generate the highest return on investment. By understating and applying Aligos Therapeutics stock analysis, traders can identify Aligos Therapeutics position entry and exit signals to maximize returns.

When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.